National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention



Similar documents
Understanding the HIV Care Continuum

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care

HIV Surveillance Update

Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results

Correlates of not receiving HIV care among HIV-infected women enrolling in a HRSA SPNS multi-site initiative

EXECUTIVE SUMMARY: INTEGRATED EPIDEMIOLOGIC PROFILE FOR HIV/AIDS PREVENTION AND CARE ELIGIBLE METROPOLITAN AREA PLANNING, PHILADELPHIA

Estimates of New HIV Infections in the United States

Integrating Medical Care Coordination Services into HIV Clinic Medical Homes

Effect of Anxiety or Depression on Cancer Screening among Hispanic Immigrants

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

Special Considerations

HIV Continuum of Care Monitoring Framework 2014

Six-Month Outcomes from a Medical Care Coordination Program at Safety Net HIV Clinics in Los Angeles County (LAC)

Running Head: INTERNET USE IN A COLLEGE SAMPLE. TITLE: Internet Use and Associated Risks in a College Sample

Illustrating HIV/AIDS in the United States

Department of Veterans Affairs National HIV/AIDS Strategy Operational Plan 2011

Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health

CHAPTER 2: Substance Use, Mental Disorders, and Access to Treatment Services in Household Surveys,

Targeted HIV Testing & Enhanced Testing Technologies. HIV Prevention Section Bureau of HIV/AIDS

Presented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention

OHIO COUNTY. Demographic Data. Adult Behavioral Health Risk Factors:

Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services

NATIONAL ADHERENCE GUIDELINES FOR HIV,TB AND NON COMMUNICABLE DISEASES

Behavioral Health Barometer. United States, 2013

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

Outpatient/Ambulatory Health Services

Health Insurance Coverage: Estimates from the National Health Interview Survey, 2004

Figure 1.1 Percentage of persons without health insurance coverage: all ages, United States,

A Ministry of the Archdiocese of Galveston-Houston A United Way Agency

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

Racial Disparities in US Healthcare

HIV/AIDS Prevention and Care

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Treatment. Race. Adults. Ethnicity. Services. Racial/Ethnic Differences in Mental Health Service Use among Adults. Inpatient Services.

UNINSURED ADULTS IN MAINE, 2013 AND 2014: RATE STAYS STEADY AND BARRIERS TO HEALTH CARE CONTINUE

2011 STI Annual Report

HIV infection in injecting drug users

Texas Diabetes Fact Sheet

Meena Abraham, DrPH, MPH Director of Epidemiology Services Baltimore City Health Department

Case Finding for Hepatitis B and Hepatitis C

Behavioral Health Barometer. United States, 2014

activity guidelines (59.3 versus 25.9 percent, respectively) and four times as likely to meet muscle-strengthening

STRATEGIC PLAN TO ADDRESS HIV IN IOWA

With Depression Without Depression 8.0% 1.8% Alcohol Disorder Drug Disorder Alcohol or Drug Disorder

POPULATION HEALTH DIVISION Transforming Public Health in San Francisco

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

Program Performance Indicators Revised Baseline & Target Setting Form January 1 June 30, 2004 Interim Progress Report

HIV/AIDS 101 Teens and Young Adults. Chara McGill

Dallas National HIV Behavioral Surveillance System 2009 Annual Data Report Injection Drug Use

HIV/AIDS in the Houston Area

SMART Objectives & Logic Modeling. HIV Prevention Section Bureau of HIV/AIDS

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Healthy People 2020: Who s Leading the Leading Health Indicators?

Project AWARE Study Overview. Lisa Metsch, PhD Grant Colfax, MD Dan Feaster, PhD

Drug Use and Abuse in San Diego County, California: 2013

Routine HIV Monitoring

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Designing Clinical Addiction Research

Integrating Mental Health and Substance Abuse Care With HIV/AIDS Prevention. John Anderson, PhD Bob Bongiovanni, MA Leigh Fischer, MPH Jeff Basinger

Maryland Population POLICY ACADEMY STATE PROFILE. Maryland MARYLAND POPULATION (IN 1,000S) BY AGE GROUP

Maryland HIV Plan

STATE OF THE HIV/AIDS EPIDEMIC IN CHARLESTON

FACILITATOR/MENTOR GUIDE

CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTH CARE AND SUPPORT SERVICES HIV MEDICATION ADHERENCE PROGRAM PROTOCOL

Testimony of. Daliah Heller, PhD, MPH Assistant Commissioner Bureau of Alcohol and Drug Use Prevention, Care and Treatment

Hepatitis C Infections in Oregon September 2014

Test Content Outline Effective Date: October 25, Psychiatric and Mental Health Nursing Board Certification Examination

Transcription:

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Age Differences in Viral Suppression, Antiretroviral Therapy Use, and Adherence Among HIV-positive Men Who Have Sex With Men Receiving Medical Care in the United States Medical Monitoring Project, 2009-2013 Nicholas DeGroote, MPH 11 th International Conference on HIV Treatment and Prevention Adherence May 9 th, 2016

CONFLICT OF INTEREST Nicholas DeGroote has no real or apparent conflicts of interest to report

BACKGROUND Diagnoses of HIV infection increased among men who have sex with men (MSM) from 2010 to 2014 with a 10% increase among the youngest group of MSM, those 13-24 years of age Viral suppression through adherence to antiretroviral therapy (ART) is essential to decrease HIV transmission and improve health outcomes National estimates of viral suppression and adherence among young MSM are lacking and the differences between young and older HIVpositive MSM have not been fully explored

OBJECTIVES To describe differences between HIV-positive MSM ages 18-24 and ages 25 or older in care in the United States in terms of: Sociodemographic characteristics Prevalence of sustained viral suppression, ART use, and adherence Depression, substance use, and ART beliefs To compare factors associated with adherence among young versus older MSM

METHODS Medical Monitoring Project (MMP) Surveillance system that produces annual cross-sectional nationally representative estimates describing the clinical and behavioral characteristics of HIV-positive adults receiving medical care in the United States Data collection Interviews and medical record abstractions Combined data from 2009-2013 cycles of MMP Response rates: Facilities: 76-85% Patients: 49-55%

METHODS Calculated weighted percentages and 95% confidence intervals among young and older MSM to estimate: Sociodemographic and behavioral characteristics Sustained viral suppression, ART use, and adherence Conducted stratified bivariate analyses to assess whether factors associated with adherence differed among young versus older MSM Depression Substance use ART medication-related beliefs All analyses accounted for unequal selection probabilities and non-response

DEFINITIONS Sustained viral suppression All HIV viral load tests in past 12 months undetectable or <200 copies/ml as documented in the medical record Current ART Use Self-reported ART use Adherent Reported taking 100% of ART doses, past 3 days Depression Symptoms of major or other depression over the past 2 weeks according to criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR)

DEFINITIONS Poverty At or below poverty threshold as defined by the Department of Health and Human Services 1 Binge drinking 5 alcoholic beverages at one sitting for men during the 30 days preceding the interview Stimulant use Stimulant use was defined as injection or non-injection use of methamphetamines, other amphetamines, ecstasy, cocaine, or crack 1 https://aspe.hhs.gov/prior-hhs-poverty-guidelines-and-federal-register-references

Demographics Among Young and Older MSM, MMP 2009-2013 Weighted % (95% CI) Demographic 18-24 (n = 361) 25+ (n = 10,487) P-value Race/Ethnicity <0.0001 White, non-hispanic 15 (10-21) 53 (48-57) Black, non-hispanic 61 (53-69) 23 (19-27) Hispanic or Latino 18 (13-23) 19 (16-21) Other 5 (3-7) 5 (5-6) Education <0.0001 <High School 14 (10-18) 8 (7-9) High School diploma or equivalent 30 (24-35) 21 (19-22) >High School 58 (51-63) 71 (70-73) Poverty <0.0001 At or below poverty level 49 (41-56) 26 (24-27)

Depression and Substance Use Among Young and Older MSM, MMP 2009-2013 Weighted % (95% CI) Depression and Substance Use 18-24 (n = 361) 25+ (n = 10,487) P-value Depression 0.16 Major depression 14 (10-18) 11 (9-11) Other depression 10 (6-14) 11 (10-11) No depression 76 (71-81) 79 (78-80) Binge drinking 32 (27-38) 18 (17-19) <0.0001 Stimulant use 12 (8-16) 12 (11-13) 0.91

ART Medication Beliefs Among Young and Older MSM, MMP 2009-2013 Weighted % (95% CI) ART Medication Beliefs 18-24 (n = 361) 25+ (n = 10,487) P-value Bothered by ART side effects* About half/most/all of the time 20 (15-25) 16 (14-17) 0.04 Sure can take ART as directed Not at all/somewhat 8 (5-11) 5 (4-5) 0.01 Sure ART has a positive effect Not at all/somewhat 13 (9-18) 10 (9-11) 0.08 Sure of resistance if non-adherent Not at all/somewhat 17 (12-21) 21 (19-22) 0.13 *Past 30 days

Percentage Sustained Viral Suppression, Current ART Use, and Adherence Among Young and Older MSM, MMP 2009-2013* 100 90 80 70 60 50 40 30 20 10 0 39 72 94 77 77 Sustained viral suppression Current ART use Adherent to ART n=10,186 n=10,186 n=9,917 *All associations: p <0.0001 18-24 25+ 89

Factors Associated With ART Adherence Among Young MSM, MMP 2009-2013 ǂ Weighted Row % (95% CI) Depression and Substance Use Adherent P-value Depression No depression 82 (77-88) <0.01 Other depression 69 (55-83) Major depression 56 (38-74) Binge drinking Yes 75 (66-85) No 78 (71-84) 0.65 Stimulant use Yes 79 (63-94) No 76 (71-82) 0.42 ǂ Limited to those currently on ART

ART Medication Beliefs Associated With ART Adherence Among Young MSM, MMP 2009-2013 ǂ Weighted Row % (95% CI) ART Medication Beliefs Adherent P-value Bothered by side effects, past 30 days About half/most/all of the time 63 (47-78) Never/rarely 80 (75-85) 0.01 Sure can take ART as directed Not at all/somewhat 54 (29-79) 0.01 Very sure/extremely sure 78 (73-84) Sure ART has a positive effect Not at all/somewhat 58 (38-78) 0.01 Very sure/extremely sure 79 (74-85) Sure of resistance if non-adherent Not at all/somewhat 77 (60-94) 0.93 Very sure/extremely sure 76 (70-83) ǂ Limited to those currently on ART

Factors Associated With ART Adherence Among Older MSM, MMP 2009-2013 ǂ Weighted Row % (95% CI) Depression and Substance Use Adherent P-value Depression No depression 90 (89-91) <.0001 Other depression 84 (82-87) Major depression 80 (78-83) Binge drinking Yes 84 (82-86) No 90 (89-90) <.0001 Stimulant use Yes 76 (72-79) No 90 (89-91) <.0001 ǂ Limited to those currently on ART

ART Medication Beliefs Associated With ART Adherence Among Older MSM, MMP 2009-2013 ǂ Weighted Row % (95% CI) ART Medication Beliefs Adherent P-value Bothered by side effects, past 30 days About half/most/all of the time 84 (81-86) Never/rarely 89 (88-90) <.0001 Sure can take ART as directed Not at all/somewhat 56 (50-61) <.0001 Very sure/extremely sure 90 (89-91) Sure ART has a positive effect Not at all/somewhat 81 (78-84) <.0001 Very sure/extremely sure 89 (88-90) Sure of resistance if non-adherent Not at all/somewhat 77 (60-94) <.0001 Very sure/extremely sure 76 (70-83) ǂ Limited to those currently on ART

Summary of Factors Associated With Non-adherence Among Young and Older MSM, MMP 2009-2013 Associated With Non-adherence Factors 18-24 25+ Depression X X Binge drinking X Stimulant use X Bothered by ART side effects X X Unsure can take ART as directed X X Unsure ART has a positive effect X X Unsure of resistance if non-adherent X X indicates significant association

DISCUSSION Compared to older MSM, young HIV-positive MSM had significantly lower prevalence of: Viral suppression (39% vs. 72%) ART use (77% vs 94%) Adherence (77% vs. 89%) Associations with adherence Depression, experiencing side-effects of ART, not taking ART as directed, and being unsure of ART s positive effects were associated with non-adherence among all MSM No significant associations between binge drinking, stimulant use, being unsure of resistance from non-adherence to ART, and adherence among young MSM

DISCUSSION Young HIV-positive MSM are more socioeconomically challenged compared to older MSM, which can create barriers to optimal healthcare Many interventions exist to improve adherence in adults, yet few rigorously evaluated tailored interventions have been developed to improve adherence among young persons Young MSM with depression reported poor adherence and thus addressing mental health may be important Providers may need to ask about and address ART side effects that their patients may experience to improve adherence among young MSM

LIMITATIONS Results are not generalizable to HIV-positive MSM that are not receiving medical care or are undiagnosed Cross-sectional analysis, causality cannot be assessed Small sample for young MSM, may have lacked power to detect other differences Not every possible factor was assessed for an association with adherence

CONCLUSION The significantly lower prevalence of sustained viral suppression, ART use, and adherence among HIV-positive young MSM supports the continued need to improve the last steps in the HIV care continuum among this group This analysis found several behavioral and attitudinal differences between young and older MSM, as well as differences in factors associated with adherence among the groups, which suggests that tailored adherence interventions may be beneficial for HIV-positive young MSM

ACKNOWLEDGMENTS Co-authors Linda Beer Christine L. Mattson Joseph Prejean Medical Monitoring Project Participants Participating facilities Local staff Community and provider advisory boards Clinical Outcomes Team at the CDC

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.